1428548-22-4

Upstream product

• 91-00-9 Benzhydrylamine 
• 23945-44-0 2,4-dihydroxypyrimidine-5-carboxylic acid 
• 1428548-45-1 5-(benzhydrylcarbamoyl)-4-hydroxypyrimidine-2-carboxylic acid 
• 1428548-44-0 N-benzhydryl-2-formyl-4-hydroxypyrirnidine-5-carboxamide 
• 1428548-43-9 N-benzhydryl-4-hydroxy-2-(hydroxymethyl)pyrimidine-5-carboxamide 
• 1428548-42-8 N-benzhydryl-2-((benzyloxy)methyl)-4-hydroxypyrimidine-5-carboxamide 
• 1428548-41-7 2-((benzyloxy)methyl)-4-hydroxypyrimidine-5-carboxylic acid 
• 1428548-40-6 ethyl 2-((benzyloxy)methyl)-4-hydroxypyrimidine-5-carboxylate 
• 1428548-12-2 ethyl N-({5-[(diphenylmethyl)carbamoyl]-4-hydroxypyrimidin-2-yl}carbonyl)-β-alaninate 

Relevant academic research and scientific papers

SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of Formula I that inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

SUBSTITUTED PYRIMIDINES

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

SUBSTITUTED PYRIMIDINES

Disclosed are substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.